Characterization of myelin pathology in the hippocampal complex of a transgenic mouse model of Alzheimer's disease

Current Alzheimer Research

Volumn 10, Issue 1, 2013, Pages 30-37

  Schmued, Larry C ^a   Raymick, James ^b   Paule, Merle G ^a   Dumas, Melanie ^c   Sarkar, Sumit ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b Toxicologic Pathology Associates   (United States)

^c Priority One   (United States)

Author keywords

AD Tg mouse; Alzheimer's disease; Amyloid plaques; Black gold II; Demyelination; Hippocampus

Indexed keywords

CONGO RED; MOLECULAR LAYER; MYELIN; TOLONIUM CHLORIDE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID PRECURSOR PROTEIN; PEPTIDE FRAGMENT; PRESENILIN 1; PSEN1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; BRAIN REGION; BRAIN TOXICITY; CONTROLLED STUDY; DEAFFERENTATION; DENTATE GYRUS; DISEASE COURSE; HIPPOCAMPAL COMPLEX; HISTOCHEMISTRY; LIMIT OF QUANTITATION; MEMORY DISORDER; MOUSE; MOUSE MODEL; MYELINATED NERVE; MYELINATION; NONHUMAN; PRIORITY JOURNAL; STRATUM LACUNOSUM MOLECULARE; TISSUE CHARACTERIZATION; TRANSGENIC MOUSE; WILD TYPE; AGE; ANIMAL; DISEASE MODEL; GENETICS; HIPPOCAMPUS; HUMAN; METABOLISM; MUTATION; MYELIN SHEATH; PATHOLOGY; STAINING;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; MYELIN SHEATH; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; PRESENILIN-1; STAINING AND LABELING;

EID: 84882358775     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011310010005     Document Type: Article

References (27)

1. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA. Molecular pathways to neurodegeneration. Nat Med 10 Suppl: S2-S9 (2004).
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356 (2002).
3. Spires TL, Hyman BT. Transgenic models of Alzheimer's disease: learning from animals. NeuroRx 2: 423-437 (2005).
4. Tsai J, Grutzendler J, Duff K, Gan WB. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci 7: 1181-1183 (2004).
5. Bartzokis G, Lu PH, Mintz J. Quantifying age-related myelin breakdown with MRI: novel therapeutic targets for preventing cognitive decline and Alzheimer's disease. J Alzheimers Dis 6: S53-9 (2004).
6. Bartzokis G, Nuechterlein KH, Lu PH, Gitlin M, Rogers S, Mintz J, et al. Dysregulated brain development in adult men with schizophrenia: a magnetic resonance imaging study. Biol Psychiatry 53: 412-21 (2003).
7. Ihara M, Tomimoto H, Kinoshita M, Oh J, Noda M, Wakita H, et al. Chronic cerebral hypoperfusion induces MMP-2 but not MMP-9 expression in the microglia and vascular endothelium of white matter. J Cereb Blood Flow Metab 21: 828-834 (2001).
8. Stricker NH, Schweinsburg BC, Delano-Wood L, Wierenga CE, Bangen KJ, Haaland KY, et al. Decreased white matter integrity in late-myelinating fiber pathways in Alzheimer's disease supports retrogenesis. Neuroimage 45: 10-16 (2009).
9. Mitew S, Kirkcaldie MT, Halliday GM, Shepherd CE, Vickers JC, Dickson TC, et al. Focal demyelination in Alzheimer's disease and transgenic mouse models. Acta Neuropathol 119: 567-77 (2010).
10. Desai MK, Mastrangelo MA, Ryan DA, Sudol KL, Narrow WC, Bowers WJ, et al. Early oligodendrocyte/myelin pathology in Alzheimer's disease mice constitutes a novel therapeutic target. Am J Pathol 177: 1422-35 (2010).
11. Schmued L, Bowyer J, Cozart M, Heard D, Binienda Z, Paule M, et al. Introducing Black-Gold II, a highly soluble gold phosphate complex with several unique advantages for the histochemical localization of myelin. Brain Res 1229: 210-217 (2008).
12. Lillie RDaHMF. Histopathologic Technic and Practical Histo-chemistry. New York: McGraw Hill 1976.
13. Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19: 939-945 (1997).
14. Bayer SA, ed. The Rat Nervous System. Forebrain, Midbrain. New York: Academic Press 1985.
15. Carpenter MB. Human Neuroanatomy. Baltimore: Williams & Wilkins 1981.
16. Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA 106: 4012-7 (2009).
17. Brendza RP, O'Brien C, Simmons K, McKeel DW, Bales KR, Paul SM, et al. PDAPP; YFP double transgenic mice: a tool to study amyloid-beta associated changes in axonal, dendritic, and synaptic structures. J Comp Neurol 456: 375-83 (2003).
18. Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol 184: 69-91 (2007).
19. Svennerholm L. Gangliosides-a new therapeutic agent against stroke and Alzheimer's disease. Life Sci 55: 2125-34 (1994).
20. Vickers JC, King AE, Woodhouse A, Kirkcaldie MT, Staal JA, McCormack GH, et al. Axonopathy and cytoskeletal disruption in degenerative diseases of the central nervous system. Brain Res Bull 80: 217-23 (2009).
21. Wirths O, Breyhan H, Schafer S, et al. Deficits in working memory and motor performance in the APP/PS1ki mouse model for Alzheimer's disease. Neurobiol Aging 29: 891-901 (2008).
22. Gold BT, Powell DK, Andersen AH, Smith CD. Alterations in multiple measures of white matter integrity in normal women at high risk for Alzheimer's disease. Neuroimage 52:1487-94 (2010).
23. Haglund M, Englund E. Cerebral amyloid angiopathy, white matter lesions and Alzheimer encephalopathy - a histopathological assessment. Dement Geriatr Cogn Disord 2002;14:161-6.
24. Ringman JM, O'Neill J, Geschwind D, Medina L, Apostolova LG, Rodriguez Y, et al. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. Brain 130:1767-76 (2007).
25. Desai MK, Sudol KL, Janelsins MC, Mastrangelo MA, Frazer ME, Bowers WJ, et al. Triple-transgenic Alzheimer's disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology. Glia 2009; 57: 54-65.
26. Okamoto Y, Ihara M, Tomimoto H, Taylor Kimberly W, Green-berg SM. Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy. Neurology 74: 93 (2010).
27. Tian J, Shi J, Bailey K, Lendon CL, Pickering-Brown SM, Mann DM. Association between apolipoprotein E e4 allele and arteriosclerosis, cerebral amyloid angiopathy, and cerebral white matter damage in Alzheimer's disease. J Neurol Neurosurg Psychiatry 75: 696-9 (2004).